PFIZER REPORTS SECOND-QUARTER 2015 RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Pfizer (PFE) PT Lifted to $41 at BMO Capital on Sum-of-the-Parts
July 29, 2015 7:30 AM EDTBMO Capital analyst Alex Arfaei reiterated an Outperform rating and boosted his price target on Pfizer (NYSE: PFE) to $41.00 (from $39.00) following Q2 results, saying the sum of the parts is looking better and said a split is becoming more likely.
Arfaei commented, "Now $41/share based on the weighted average of DCF ($37,... More
Pfizer (PFE) Tops Q2 EPS by 4c
July 28, 2015 7:01 AM EDTPfizer (NYSE: PFE) reported Q2 EPS of $0.56, $0.04 better than the analyst estimate of $0.52. Revenue for the quarter came in at $11 billion versus the consensus estimate of $11.42 billion.
Raised Midpoints of 2015 Financial Guidance Ranges for Reported Revenues by $500 Million and Reported and Adjusted(2) Diluted EPS by $0.03 and $0.04, Respectively, Due to Strong Performance to Date and Improved Business Outlook
EXECUTIVE COMMENTARY
Ian Read, Chairman and Chief Executive Officer, stated, Our second-quarter and year-to-date financial performance is the result of continued business... More
